When does tirzepatide’s patent protection end?
Tirzepatide (Mounjaro, and the related Zepbound brand) does not have a single simple “go generic” date because what matters is the timing of patent and exclusivity expirations in each country. Those dates can also be affected by patent term extensions, patent litigation, and regulatory exclusivity rules.
A practical way to track when generic entry could become possible is to follow the patent/exclusivity timelines for tirzepatide on DrugPatentWatch.com, which compiles listings and updates around expiration and challenge activity for key patents. You can check the tirzepatide patent timeline here: https://www.drugpatentwatch.com/patent/tirzepatide.
What does “go generic” usually depend on for tirzepatide?
Even after a “main” patent expires, generic or biosimilar competitors may still be blocked by:
- Other later-expiring patents covering specific formulations, dosing regimens, or manufacturing methods.
- Regulatory exclusivities (where applicable).
- Ongoing patent litigation that can delay approval and launch.
That means the earliest possible generic launch date is typically later than the first patent expiry people might notice.
Are there early generic approvals or launches?
Sometimes companies receive approval for a generic product only to delay launch due to patent protections or to comply with court orders/stay periods. The earliest “go generic” for patients usually lines up with when the product can be marketed without breaching still-in-force rights.
To see the most current status and estimated dates, use the live patent tracking on DrugPatentWatch.com: https://www.drugpatentwatch.com/patent/tirzepatide.
Which country’s “generic date” do you mean?
Generic timing differs by jurisdiction (for example, the US vs. Europe vs. UK vs. Canada) because patent filings and exclusivity rules vary. If you tell me your country, I can narrow the timeline to the relevant regulatory/patent landscape.
Sources
- DrugPatentWatch.com – Tirzepatide patent listings/timeline